Endogenous retrotransposon sequences constitute approximately 42% of the human genome, and mobilisation of retrotransposons has resulted in rearrangements, duplications, deletions, novel transcripts and the introduction of new regulatory domains throughout the human genome. Both germline and somatic de novo retrotransposition events have been involved in a range of human diseases, and there is emerging evidence for the modulation of retrotransposon activity during the development of specific diseases. Particularly, there is unequivocal consensus that endogenous retrotransposition can occur in neuronal lineages. This review addresses our current knowledge of the different mechanisms through which retrotransposons might influence the development of and predisposition to amyotrophic lateral sclerosis.
This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: http://creativecommons.org/licenses/by/4.0/
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease, is characterised by the rapid progressive degeneration of the upper and lower motor neurons. This results in the wasting and weakening of the muscles of the limbs and trunk and those involved in speaking, swallowing and facial expression. It is usually fatal within 3–5 years of disease onset, most frequently due to respiratory failure.1 In European populations, the incidence of ALS is 2.16 per 100 000 people per year, and the median age at diagnosis is 65.2 and 67 years for men and women, respectively.2 The mechanisms underlying the pathogenesis of ALS are not fully understood; however, there have been several hypotheses proposed to explain what drives the development of the disease, which include protein aggregation, oxidative stress, excitotoxicity and defects in RNA processing and axonal transport.3 Of the cases of ALS, 5%–10% are reported as familial and the remaining as sporadic. However, this division may not accurately reflect the mechanisms and risk associated with disease development.S1 Familial ALS is defined by a positive family history of the disease, but family history may not always be apparent, has varying definitions and many of the mutations identified in cases of familial ALS are also found in those with the sporadic form.4 S2 Twin studies estimate a heritability of 60% in sporadic ALS, and first-degree relatives of patients with sporadic ALS have an eightfold increased risk of developing the disease, demonstrating further the importance of genetics in the sporadic disease.S3 S4 There have been more than 30 genes associated with familial and sporadic ALS and more genetic risk loci identified through genome-wide association studies (GWAS).5 6 The four genes harbouring mutations that cause the greatest number of ALS cases are SOD1, C9orf72, FUS and TARDBP, contributing to 47.7% and 5.2% of familial and sporadic cases, respectively, in a recent meta-analysis of European and Asian populations.7
The increase in the generation and availability of sequencing data has driven the discovery of new genes involved in the development of ALS, with the rate of discovery doubling every 4 years.S5 Despite these findings there is still much to learn about the genetic causes of ALS and how variants affect disease progression. The same mutation in different individuals does not always result in the same clinical progression or even the same disease. The C9orf72 repeat expansion and mutations in FUS and TARDBP can lead either to the development of ALS or frontotemporal lobar degeneration (FTLD).8 Additional modifying genetic variants and environmental factors or a combination of both are likely to contribute to the phenotypic heterogeneity seen in carriers of these mutations. For example, the intermediate length trinucleotide CAG repeats encoding polyglutamine tracts in the ATXN2 gene that confer a risk of developing ALS have been associated with C9orf72 repeat expansion carriers with ALS but not with those carriers with FTLD.9 10 Environmental factors have also been implicated in ALS pathogenesis, but it has proven difficult to replicate these experimental outcomes reliably. Proposed environmental risk factors include physical exercise and exposure to heavy metals, pesticides and electromagnetic radiation.5 11 Modelling of the population with ALS suggests ALS development is a multistep process requiring six molecular steps, and these are likely to be a combination of genetic and environmental factors.12
One component of the human genome that has been largely overlooked in conjunction with neurodegenerative diseases until recently is the group of endogenous transposable elements (TEs), even though such structures contribute to nearly half of our genome. Their role in evolution, disease, regulation of gene expression, response to environmental stimuli and their ability to generate genetic diversity both within a population and within an individual have led to them no longer being considered ‘junk’ DNA but an important part of the human genome.13–15 Two classes of TEs can be identified in mammalian genomes:
DNA transposons are widely represented in different taxa of organisms including vertebrates. Functional transposons encode a transposase protein, flanked by two terminal inverted repeats (figure 1A), and move by a ‘cut-and-paste’ mechanism that involves excising an element and its reinsertion at a new genomic location.S6 On insertion, a sequence in the target site is duplicated, generating a target site duplication (TSD).S7 DNA transposon sequences account for around 3% of the human genome but, with the exception of at least one family of PiggyBac elements in little brown bats,S8 no functional DNA transposons have been identified in mammals to date.
Retrotransposons comprise approximately 42% of the human genome and propagate via a ‘copy-and-paste’ mechanism, meaning that retrotransposon transcripts are reverse-transcribed into a complementary DNA (cDNA) intermediate which is integrated into a new site of the host genome by retrotransposon-encoded proteins. Retrotransposons can be subdivided into long terminal repeat (LTR) retrotransposons and non-LTR retrotransposons (figure 1B).16 This review will bring retrotransposons into sharper focus and discuss how their activity could contribute to the development and progression of ALS.
Human endogenous retroviruses (HERVs) belong to the class of LTR retrotransposons that constitute approximately 8% of the human genome. They are flanked by LTRs which contain transcriptional regulatory domains controlling expression of the proviral DNA but have also been exapted as regulatory elements for endogenous genes (figure 2).S9 S10 Endogenous retroviruses resulted from the repeated infection of germ cells by exogenous retroviruses and became unable to reinfect due to mutations that accumulated in their proviral DNA.17 As a consequence, expression of endogenous retrovirus proviral DNA does not lead to infectious particles, and there is currently no evidence that endogenous retroviruses still mobilise in humans, although this cannot be ruled out.17 18 The classification of HERVs is complex and dependent on the methodology used, with HERVs divided into 50–200 families.19 One of the methods is primarily based on the tRNA that binds to the viral primer binding site which for HERV-K is the lysine (K) tRNA, and the most recent inherited proviral insertions in the human genome are the HERV-K sequences.17 A complete autonomous HERV-K sequence harbours 7–9 kb of DNA coding for the viral proteins gag, pro, pol and env, and is flanked by ~1000 bp LTRs (figure 1B). There are a small number of complete HERV-K elements in the human genome; however, the majority of HERV families no longer encode functional proteins, and in many cases the only remnant of the HERV integration is a solo LTR due to the removal of the originally LTR-flanked region by recombination events. HERV-K insertions are present in Old World monkeys, apes and humans, and are likely to have entered the primate lineage after the divergence of New and Old World monkeys.S11 Similarities in sequence allow for the identification of 10 HERV-K families (HML-1 to HML-10), and a number of HML-2 loci, the youngest family, are human-specific, indicating their continued mobilisation during human evolution.18 Recent reports have also identified polymorphic HERV-K insertions for their presence/absence in humans,20 suggesting recent mobilisation activity and the possibility that some HERV-K copies might currently still retain the capability to mobilise in present-day humans. Multiple neurological diseases, including multiple sclerosis, schizophrenia and ALS, have been associated with HERVs, and HERV-K is the predominant family studied in the pathogenesis of ALS, but a direct cause–effect relationship has yet to be proven.21 S12
Non-LTR retrotransposons lack LTRs, include the families of long interspersed nuclear element-1 (LINE-1/L1), short interspersed nuclear elements (SINEs) and SINE-VNTR-Alu (SVA) retrotransposons in humans (figure 1B), and represent the only group of TEs that is still currently mobilised in the human genome.16 The LINE-1 subfamily represents the only autonomous group of human non-LTR retrotransposons because members of this subfamily encode those proteins that are essential for their mobilisation and there are 80–100 retrotransposition competent LINE-1 elements in the human reference genome.22 A functional, full-length LINE-1 element is ~6 kb in length, contains a 5’ and 3’-untranslated region (UTR), three open reading frames (ORF0, ORF1, ORF2) whereby ORF1 and ORF2 are separated by a 63bp spacer region, a poly A-tail at its 3’ end, and is flanked by variable length TSDs (figure 1B). The 5’ UTR includes a sense and antisense promoter. ORF1p is a ~40kDa protein with RNA binding and chaperone activities.S13 ORF2p has a molecular weight of ~150kDa and harbours endonuclease (EN)S14 and reverse transcriptase (RT) activities23 (figure 1B). Both ORF1p and ORF2p are essential for retrotransposition of their own mRNA in cis which is performed by a mechanism termed target-primed reverse transcription (figure 3). This mechanism involves the nicking of the bottom strand of the target DNA by the EN domain of ORF2p to expose a 3’hydroxyl for priming reverse transcription of LINE-1 mRNA by the RT domain of ORF2p.S15 Due to the presence of a conserved antisense promoter in full-length LINE-1 elements,S16 a third ORF named ORF0 has recently been identified in selected human LINE-1 elements with ORF0p enhancing their retrotransposition.S17 The non-autonomous non-LTR retrotransposons Alu and SVA do not have any protein-coding capacity and recruit the LINE-1 protein machinery for their own mobilisation in trans. Alu elements are primate-specific SINEs derived from the 7SL RNA gene, and there are approximately 1.5 million copies in the human genome (figure 1B).24 SVAs are hominid-specific composite elements consisting of a 5’ hexamer repeat that can be variable in length ((CCCTCT)n), two Alu fragments in antisense orientation, a GC-rich variable number tandem repeat (VNTR), a SINE-R sequence derived from an HERV-K10 element and a poly-A tail following a polyadenylation signal (figure 1B).25 The continuing expansion of non-LTR retrotransposons has contributed to more than a third of the human genome shaping its organisation and gene expression through a variety of mechanisms, including insertional mutagenesis, deletions at the insertion site, 5’- and 3’ transductions, non-allelic homologous recombination, transcript pausing or termination, antisense/sense promoter effects, alternative splicing, heterochromatisation and processed pseudogene formation.13 16 Furthermore, non-LTR retrotransposon insertions can affect host gene expression by numerous mechanisms (figure 4).
It is well established that new LINE-1, Alu and SVA mobilisation events occur in most instances during early embryogenesis and to some extent in germ cells.26 The neuronal lineages in hippocampus, cerebellum, caudate nucleus and cortex (reviewed in ref 26) support mobilisation of human endogenous LINE-1 elements, and LINE-1-mediated insertions occur throughout fetal and adult neurogenesis as well as in mature neurons, resulting in somatic mosaicism in the adult brain.27–31 LINE-1 retrotransposition has also been demonstrated in tumour cells, resulting in somatically acquired insertions in cancer genomes (reviewed in S18). De novo retrotransposition events that occur in germ cells and during early embryonic development prior to partitioning of the germline are heritable and create genetic variation in the population, whereas those occurring in somatic tissues will not be passed on to the next generation but could influence cellular function and fitness of the individual.
Detection of reverse transcriptase activity in patients with ALS
It has been hypothesised that retroviral activity may, at least in part, be involved in ALS development.32 Evidence for this hypothesis includes motor neuron dysfunction in mice caused by a retroviral infection, the identification of antibodies in the sera of patients with ALS directed against retroviral proteins of the human T-lymphotrophic virus and the development of ALS-like syndromes in patients infected with the human T-lymphotrophic virus-1 and HIV.32 S19 S20 Also, patients with HIV-associated ALS syndrome may experience improvement in such symptoms with antiretroviral treatment.33 34 Both retroviruses and autonomous retrotransposons encode an RT enzyme generating a cDNA copy of the proviral and retrotransposon-encoded mRNA, respectively.17 23 RT activity was detected in 59% of sera from patients with ALS, but only in 5% of sera from an unaffected control group, but it could not be attributed to the presence of any known human exogenous retrovirus.35 A second study also detected a significant difference in RT activity in the sera of patients with ALS compared with non-blood relative controls (spouses and healthy volunteers) (47% vs 18%); however, there was only a small difference in RT activity when comparing patients with ALS with blood relative controls (first degree, aunt or cousin) (47% vs 43%).36 Comparable levels of RT activity in blood relative controls of patients with ALS and the absence of any detectable exogenous retrovirus suggest that the origin of the RT activity is endogenous. A recent study demonstrating the activation of an endogenous retrovirus in at least a subpopulation of patients with sporadic ALS37 suggests that this endogenous RT is at least one source of the detected RT activity. Determining any potential role of RT in the pathogenesis of the disease is hugely important to improve our understanding of the development of ALS. If the increase in RT activity in ALS was shown to have a causative role in the pathogenesis of the disease, well-established RT inhibitors may provide a viable target for treatment.
Global changes to TE regulation in ALS
There is evidence for a global activation of TEs in ALS, which includes both LTR and non-LTR retrotransposons, and TEs belonging to both retrotransposon, and DNA transposon classes are regulated by TAR DNA-binding protein 43 (TDP-43), a protein involved in neurodegenerative disorders including ALS, FTLD and Alzheimer’s disease.8 S21 As previously stated, mutations in the TARDBP gene encoding the TDP-43 protein have been identified in both familial and sporadic cases of ALS and FTLD.7 Moreover, the accumulation of TDP-43 in the cytoplasm occurs in the majority of ALS and 45%–60% of FTLD cases.S22 S23 TDP-43 is a nucleic acid binding protein with distinct binding affinities for RNA and DNA and is involved in the regulation of transcription and splicing, miRNA processing, and the stability and transport of mRNA.S24 One study found that transcripts derived from LTR and non-LTR retrotransposons and DNA transposons are targets of TDP-43 in humans, rats and mice, and that this association of TDP-43 and TE transcripts is decreased in the brain tissue of patients with FTLD compared with controls.38 This study also demonstrated that in two different mouse models of TDP-43 dysfunction (overexpression and striatal depletion), TE transcripts were overexpressed; the authors hypothesised that TE overexpression may be part of TDP-43 pathology and contribute to TDP-43-related neurodegeneration. Another model system of ALS using Drosophila melanogaster, in which the expression of human TDP-43 in either neurons or glia resulted in protein aggregation, motor impairment and premature death, was used to investigate the relationship of TDP-43 and TEs further.39 Human TDP-43 overexpression was found to be correlated with elevated expression of members of the class of LTR retrotransposons and LINE families in Drosophila due to the loss of small interfering RNAs that act post-transcriptionally to repress these elements. Further, they found that the expression of human TDP-43 and activation of retrotransposon expression caused cell death through DNA damage-mediated signalling. It was shown that this type of toxicity in glial cells was due to the activity of the endogenous retrovirus gypsy as the phenotype could be rescued when gypsy expression was inhibited either genetically or pharmacologically (RT inhibitors). The data suggest that the activation of retrotransposons could be contributing to TDP-43-mediated neurodegeneration, which includes ALS and FTLD. Similarly, a study analysing the transcriptome of the frontal cortex and cerebellum of patients with ALS demonstrating C9orf72 GGGGCC repeat expansions, identified a significant increase in transcripts from both classes of TEs (retrotransposons and DNA transposons) in the frontal cortex when compared with controls.40 Although C9orf72 expansion-negative patients with ALS also demonstrated a similar trend of increased TE expression in the frontal cortex, this was not statistically significant. The study did not find an association either between TDP-43 levels or pathology and the increase in TE transcripts; however, the changes observed positively correlated with RNA polymerase II activity. The data suggest that there was a global change in TE expression and activity in the brains of certain patients with ALS, and the exact role, if any, of the different TE families in disease progression is still to be determined. Table 1 summarises the findings from these studies linking TE expression to ALS and FTLD. In addition, several other neurological diseases have been associated with retrotransposon activity, more specifically LINE-1, including Rett syndrome, ataxia telangiectasia, autism and schizophrenia,S25–S29 and therefore the dysregulation of retrotransposons may be part of the ALS disease process and play a wider role in neurological conditions.
Activation of endogenous retroviral expression in ALS
Several studies have been carried out, outlined below, implicating a role of HERV-K-derived gene products in the pathogenesis of ALS. There is a significant increase in HERV-K pol expression in cortical brain tissue from patients with ALS compared with non-ALS controls.41 HERV-K pol levels from the HML-2 and HML-3 subfamilies differ across brain regions in patients with ALS but not in the non-ALS controls, as do the genomic loci where the transcripts originate, suggesting unique patterns of expression in the brains of those with ALS. Immunohistochemistry shows the presence of HERV-K RT protein is limited to neurons and at significantly higher levels in patients with ALS than in controls.41 In a subsequent study, transcripts of the gag, pol and env HERV-K genes were elevated in the brain tissue from patients with ALS over controls, and expression of the HERV-K HML-2 Env protein was detected in the cortical and spinal neurons of patients with ALS but not in normal or Alzheimer’s disease brain tissue.37 Although this provides evidence for the presence of HERV-K expression in ALS, it is not clear if this is part of the pathogenic process or a consequence of it. To elucidate the potential role of HERV-K in the pathogenesis of ALS, a transgenic mouse line expressing the HERV-K HML-2 Env protein in neurons has been generated.37 The transgenic animals develop progressive motor neuron degeneration involving both the upper and lower motor neurons, atrophy of the motor cortex, DNA damage and morphological abnormalities of the neurons resulting in a 50% mortality rate by 10 months, suggesting that HERV-K expression is a cause rather than a consequence. Additionally, transfection of the HERV-K HML-2 genome or HERV-K HML-2 env gene alone into human neuronal cells causes a decrease in cell number and retraction of neurites.37 In contrast to the above studies, a recent report did not detect any compelling differences in the transcription of HERV-K HML-2 loci in ALS versus control brain and spinal cord samples and was unable to confirm the presence of full-length HML-2 Env protein in ALS and control samples.42 Table 1 summarises the data from the above studies.
A recent report on five patients with HIV with motor neuron disease analysed the HERV-K RNA expression level in response to antiretroviral therapy.33 Data on HERV-K RNA levels at the onset of neurological symptoms were available for two patients who showed elevated HERV-K expression levels in plasma that became undetectable after treatment with antiretroviral therapy.33 HIV-1 infection is known to induce HERV-K expression, so it is unclear whether the antiretroviral therapy directly inhibits HERV-K or the reduction in HERV-K RNA is due to a loss of activation by HIV-1.S30 Clinical trials are currently under way testing the ability of antiretroviral therapy to suppress HERV-K expression and the safety and tolerability of these drugs in patients with ALS (NCT02437110, NCT02868580 and Motor Neurone Disease Australia’s The Lighthouse Project). The results of these trials will be important in determining if the potentially pathogenic expression of this element could be modified with existing drugs.
Germline retrotransposon insertion polymorphisms
De novo retrotransposition events are detectable in approximately 1 of 20 live births for Alu elements, 1 of 150 for LINE-1 and 1 of 1000 for SVA elements, and within the global human population there are an estimated 392 million private insertions unique to those harbouring them.14 It is estimated that every human has on average 180 LINE-1, 1283 Alu and 56 SVA presence/absence insertion polymorphisms,43 which are an important source of genetic variation. Genetic variants generated by the presence or absence of these retrotransposons are termed retrotransposon insertion polymorphisms (RIPs). Due to the complex nature of the analysis, this type of genetic variation is not routinely studied in large cohorts, although there are a wide range of bioinformatics tools available to analyse such variation.44 To date, no actively retrotransposing HERV elements have been reported to be able to create new insertions in the human genome. However, 36 polymorphic HERV-K insertions have been identified that are not present in the human reference genome in a study analysing over 2500 genomes.20 The few polymorphic HERV-K insertions are therefore a much smaller source of genetic variation compared with the huge number of polymorphic non-LTR retrotransposon insertions. To date, 124 different LINE-1-mediated insertions have been identified as the genetic cause of diseases such as hereditary cancer, haemophilia, X linked dystonia parkinsonism and neurofibromatosis type 1.15 Mechanisms by which LINE-1-mediated de novo retrotransposition events affect the respective disease-related host genes include gene inactivation through aberrant splicing and exonic insertions causing frameshifts, deletions at the site of insertion and also the incorporation of the element’s sequence into the host protein affecting its function.15 Many of these disease-causing events are rare insertions resulting in a robust phenotype, but there are also more common RIPs that have been shown to affect the function of the gene they have inserted into. For example, a SVA-E insertion into intron 8 of the CASP8 gene is associated with transcript abnormalities and with an increased risk of breast cancer but a decreased risk of prostate cancer.45 There is also evidence for common Alu RIPs as candidate causative variants in diseases such as multiple sclerosis when identified to be in linkage disequilibrium with trait-associated single nucleotide polymorphisms (SNPs) identified through GWAS.46 A study into the impact of RIPs on human health and disease through changes in gene expression included a global analysis of LINE-1, Alu and SVA RIPs in linkage disequilibrium with SNPs associated with complex diseases from GWAS, and found 2474 such elements in a European population.47 This study, using a focus on the human immune system, identified candidate RIPs that could lead to the disease through changes in gene regulation.47 LINE-1 RIPs have also been shown to be enriched in intragenic regions and different gene ontologies and pathways when those found in controls were compared with individuals with schizophrenia.S29 Analysis of SNP variation demonstrated there is a 14.3% genetic correlation between ALS and schizophrenia, suggesting convergent biological mechanisms between the two diseases.S31 The burden of RIPs within an individual will vary, and therefore the genes and pathways affected by their presence could also differ.
There are data available on those RIPs that have already been identified, collated in a review44 and in databases such as the European database of L1-HS retrotransposon insertion in humans (euL1db.unice.fr). There have also been large-scale studies addressing RIPs in the 1000 genomes data.S32 So far, this list comprises approximately 40 000 Alu, LINE-1 and SVA RIPs in the human populations studied, but it will grow as further genomes are analysed. This list of RIPs includes several that are present in genes and genetic loci that are associated with ALS. It is possible that these retrotransposon insertions affect splicing and expression of the gene where they inserted through the introduction of novel splice sites and regulatory domains (figure 4 for major mechanisms).15 47 We propose that these RIPs and others that have yet to be identified have the potential to alter the function or expression of the genes they have inserted into and could act as genetic predisposing factors for ALS. Extensive analysis of those pathways containing genes potentially affected by RIPs is beyond the scope of a review. However as an example the NEK1 locus, a gene recently identified to contain risk variants for ALS and involved in mitochondrial function and DNA damage response,48 has both reference non-LTR retrotransposon insertions and RIPs that could impact on the regulation and function of this gene. To explore this hypothesis, RIPs would need to be addressed in patients with ALS and controls to determine if there are insertions that occur more frequently in one population compared with the other. The functional consequences of any insertions identified that are associated with disease risk would need to be investigated further. One such experiment could involve developing a cell culture model of induced pluripotent stem cells from patients harbouring the insertion, which could then be removed using CRISPR to evaluate the consequences of the specific insertion on host gene expression.
Somatic mobilisation of non-LTR retrotransposons in the brain
Non-LTR retrotransposons can affect cellular function through insertions in the germline but also via their mobilisation in adult tissues, which includes neuronal cells. The evidence for the mobilisation of non-LTR retrotransposons in neuronal cells has come from a combination of studies using cell lines, animal models and human tissue. By applying engineered LINE-1 retrotransposition reporter elements in cell culture assays, it was demonstrated that rat neuronal progenitor cells, human fetal brain neuronal progenitor cells, neuronal progenitor cells derived from human embryonic stem cells and mature non-dividing neurons can support human LINE-1 retrotransposition in vitro.28–30 In addition, an enhanced green fluorescent protein marked human LINE-1 retrotransposition reporter transgene in mice resulted in somatic mosaicism in the brain.30 A quantitative multiplexed PCR assay to determine the endogenous LINE-1 copy number in a given genome demonstrated that there is an increase in LINE-1 copies in several brain regions compared with the heart and liver from the same human individual, with the highest number found in the hippocampus.28 Using a technique termed retrotransposon capture sequencing, endogenous somatic retrotransposition events in the human brain were identified and characterised.49 50 Retrotransposon capture sequencing was used to generate libraries of retrotransposon insertions in genomic DNA from the hippocampus and caudate nucleus of three donors of advanced age (average 92 years old). Subsequent next-generation sequencing identified 7743 LINE-1, 13 692 Alu and 1350 SVA putative somatic de novo insertions in total in the three individuals which were present in one brain region but absent in the other and not previously identified as a germline variant.49 Thirty-three of these potential de novo insertions were chosen for validation by genotyping PCR and capillary sequencing of the resulting PCR products, successfully validating 28 of them as somatic de novo insertions that were absent from the second brain region.49 The number of neurons affected by an individual somatic de novo insertion would be dependent on the point in time of the retrotransposition event, whether it occurred in a single mature postmitotic neuron, during neurogenesis or early in embryonic development affecting neuronal lineages. Therefore, characterising the extent of this neuronal mosaicism is challenging.26
Single cell-based analysis of somatic retrotransposition events suggests retrotransposition frequencies of 0.2–16.3 new insertions per neuron depending on the brain region and type of analysis.50–52 Although the actual rate of somatic retrotransposition in neurons is still an area of controversy, somatic insertions have been validated and characterised, showing that the genome of an individual or groups of neurons can be altered by these elements. Even taking the lowest rate of 0.2 per neuron would result in 20 billion unique insertions in the adult human brain.53 In the adult brain, somatic insertions are more likely to occur into expressed genes due to their open chromatin. It is hypothesised that a controlled level of somatic retrotransposition in neuronal genomes may be beneficial in generating diversity between neurons, thus enabling individuals to respond to their environment, and could be a mechanism involved in memory and learning.27 49 Conversely, increased non-LTR retrotransposon activation beyond what may be beneficial and the misregulation of these mobile elements could contribute to neurodegeneration and cognitive decline. Changes to the chromatin structure and derepression of retrotransposons during ageing have been associated with their increased transcript expression. This increase in retrotransposon mRNA expression and evidence for mobilisation has been identified for non-LTR retrotransposons in replicatively senescent human cells (normal diploid fibroblasts), both LTR and non LTR retrotransposons in the ageing mouse (liver and muscle tissue), and LINE-like and LTR retrotransposons in the brain of Drosophila where it was linked to cognitive decline.54–56 Age is a risk factor for many neurodegenerative conditions, and changes to retrotransposon regulation during ageing may be part of this increasing risk for disease. Although mRNA and retrotransposon encoded proteins have been shown to be upregulated in ALS, it has yet to be determined if there is an increase in somatic retrotransposition events in the brains of patients with ALS and whether the site of insertion could affect the normal functioning of those neurons.
ALS is thought to be a multistep process involving a complex interplay between germline genetic variation that defines the level of risk an individual is born with and subsequent modifiers we are confronted with as we age, such as the environment, which determines whether an individual develops the disease or not. The presence or absence of retrotransposon insertions contributes extensively to germline genetic variation affecting the structure, splicing and expression of genes. To date, this type of genetic variation has not yet been addressed in ALS cohorts and should not be overlooked as a potential source of germline risk to the disease. The regulation of these retrotransposons is modified by age and in neurological disorders, including ALS, and can alter the genome of individual or groups of neurons in the adult brain. The changes in the regulation of retrotransposon insertions and the consequences of genomic alterations caused by somatic retrotransposon mobilisation could affect normal cellular function and even lead to cell death, contributing to later steps of the disease development process. Further studies are required to fully investigate the exact role of retrotransposons and determine if there is a direct cause and effect relationship between retrotransposon activity or individual retrotransposon insertions and neurological diseases. Retrotransposons have the potential to be involved in the multiple steps of the development of ALS, from contributing to the missing heritability of the disease to neuronal dysfunction and degenerative processes. Additional references can be found in online supplementary file 1.
Contributors The majority of the text was written by the first author (ALS), with contributions from all authors (GGS, JPQ, VJB, AA-C and GB). The figures were generated by GGS and ALS. This work is part of an ongoing project funded by the MNDA (grant 41/523) of which all authors are part.
Funding This study was funded by the Motor Neurone Disease Association (Grant Number: 41/523). ALS, JPQ, GGS, VJB, GB and AA-C are funded by the Motor Neurone Disease Association and JPQ by the Andrzej Wlodarski Memorial Research Fund. For AA-C this work is supported through the following funding organisations under the aegis of JPND—www.jpnd.eu (UK, Medical Research Council (MR/L501529/1; MR/R024804/1) and Economic and Social Research Council (ES/L008238/1)), and through the Motor Neurone Disease Association, and represents independent research part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The work leading up to this publication was funded by the European Community’s Horizon 2020 Programme (H2020-PHC-2014-two-stage; grant agreement number 633413).
Competing interests None declared.
Patient consent Not required.
Provenance and peer review Not commissioned; externally peer reviewed.